Glaxo Group Ltd. operates through its subsidiary Glaxo Laboratories Ltd. that engages in the production of food products for infants such as Ostermilk, Complan, Casilan, Farex. Glaxo Group Ltd. was formerly known as Glaxo Laboratories Ltd. and changed its name to Glaxo Group Ltd. in 1962. The company is based in Brentford, United Kingdom. Glaxo Group Ltd. operates as a subsidiary of Glaxosmithkline plc.

Servier are driven by the belief in the excellence of their profession. Theirs is a research-based organization, fulfilling a basic need and dedicated to the future.

Sichuan Credit Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of products related to central nervous system. Its products include capsules, tablets, freeze-dried powder injections, water injections, anti-tumor solid preparations, and traditional Chinese medicines. The company was founded on April 20, 2000 and is headquartered in Luzhou, China.

A. Carlsson Research AB, part of NTG Nordic Transport Group A/S, is a Swedish company located in Gothenburg that develops and discovery and clinical development of new pharmacological treatment principles for psychiatric and neurological disorders. Arvid M. Carlsson is currently the CEO of the firm. NTG Nordic Transport Group An acquired A. Carlsson Research AB on October 23, 2006 for $121.91 million.

CuraGen Corporation is a biopharmaceutical development company that develops novel therapeutics for the treatment of cancer in the United States and Europe. Its therapeutics is based on novel targets from the human genome that play a role in proven mechanisms underlying disease. The Company's strategy continues to be focused on advancing its pipeline of pipeline of protein, antibody, and small molecule drugs in the areas of oncology, inflammatory diseases, and diabetes, promising therapeutics through clinical and preclinical development. CuraGen Corporation was founded in 1991 and is headquartered in Branford, Connecticut. As of October 1, 2009, CuraGen Corporation operates as a subsidiary of Celldex Therapeutics, Inc.

Serodus ASA is a private Scandinavian drug development company. They focus on developing new treatments with unmet clinical needs in the areas of diabetes and diabetic comorbidities. Their business model is to in-license drug candidates at an early stage. After having demonstrated clinical effects in humans during clinical phase II, they partner with international pharmaceutical companies. Serodus manages the business processes through their extensive network of contract organizations. They are a virtual organization and have no laboratories of their own. The Serodus Management Team combines the weight of Big Pharma experience with the agility of BioPharm decision making and action. The combined experience of their seasoned leadership team spans research, clinical development, business development, and financing. Their individual track records pave the way for long-term success. All drug candidates are covered by extensive intellectual property (patents and patent applications) held by or licensed to Serodus.

Organon Pharma (UK) Ltd. develops and manufactures pharmaceuticals. It offers osteoarthritis pain treatment Arcoxia, cardiovascular medication Cozaar, HIV drug Crixivan and asthma treatment Singulair. It operates a research center specializing in the development of central nervous system disorder such as Alzheimer's disease, depression, anxiety and migrane. The company was founded in 1953 and is headquartered in Hoddesdon, the United Kingdom.

Genaissance Pharmaceuticals, Inc. develops and uses genetic information to diagnostic and therapeutic products. The company was founded by Kevin L. Rakin and Gualberto Ruano in 1992 and is headquartered in New Haven, CT.

F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

NovaDel Pharma Inc. is a specialty pharmaceutical company engaged in the development of novel drug delivery systems for prescription and over-the-counter drugs. The Company's proprietary oral spray technology delivery system offers the patient the potential for (i) more rapid delivery of drugs to the bloodstream allowing for quicker onset of therapeutic effects compared to conventional oral dosage forms; (ii) increased bioavailability of a drug by avoiding metabolism by the liver; (iii) improved drug safety profile by reducing the required dosage, including possible reduction of side effects; (iv) improved dosage reliability; (v) allowing medication to be taken without water; (vi) avoiding the need to swallow as is the case with many medications; and (vii) improved patient convenience and compliance. The Company plans to develop such products independently and through collaborative arrangements with major pharmaceutical and biotech companies.

Grünenthal GmbH engages in the research and development of pharmaceutical products. It specializes in pain, gout, and inflammation. The company was founded by Hermann Wirtz in 1946 and is headquartered in Aachen, Germany.

Suzhou Kangrun Pharmaceutical Co., Ltd., established on 2010-01-06, Business scope includes pharmaceutical products,Research and development of pharmaceutical intermediates,Provide relevant technical advice,technology transfer,Technical Services;Self-operated and agent import and export business of various commodities and technologies.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments) licensed items:pharmaceutical production(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results)

Spexis Ltd. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of respiratory therapeutics. The firm focuses on rare, chronic respiratory diseases (CRD) and chronic lung infections in cystic fibrosis. Its product pipeline includes ColiFin, Inhaled Murepavadin, Balixafortide (POL6326), OMPTA, EBX-002, and POL6014 (Lonodelestat). The company was founded by Daniel Obrecht and Jean-Pierre Obrecht in 1996 and is headquartered in Allschwil, Switzerland.

Sichuan Chuanmei Glauber's Salt Co., Ltd., established on 2001-06-01, Business scope includes production and sales of Yuanming powder,Medicinal Glauber's Salt,Xuanming powder,Anhydrous Sodium Sulfate,potassium sulfate,Sodium silicate,Chemical machinery,interior paint;Self-provided power generation(country ban,Except for special approval and products involving quota licenses).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

AstraZeneca has always believed in science, inspires infinite possibilities, and puts science at the top of all work. AstraZeneca's strategically important core treatment areas, and are committed to exploring pathogenic mechanisms, treatment methods, and innovative drugs, so that science can change people's lives and bring it to the medical industry Significant changes.

Adaptimmune Ltd. develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. It utilizes the T cell to target and destroy cancerous and infected cells by using affinity T cell receptor proteins as a means of strengthening patient T cell responses. The company was founded by Bent K. Jakobsen, James Julian Noble and Helena Katrina Tayton-Martin in 2008 and is headquartered in Oxford, the United Kingdom.

Immunocore Ltd., part of Immunocore Holdings Plc, is a company headquartered in Oxon, UK. The firm develops and commercializes transformative medicines for cancer, infection and autoimmune disease. It was founded in 2007. Bahija Jallal is the current CEO of the firm.\nThe company says this about itself: Immunocore is a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, autoimmune, and infectious disease. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs.

Smithkline Beecham Ltd. manufacture of basic pharmaceutical products. It also provides mineral water, bottled water, and soft drinks. The company was founded on January 24, 1989 and is headquartered in Brentford, the United Kingdom.

Luzhou Creed Pharmaceutical Co., Ltd., established on 2007-07-20, Business scope includes research and development of APIs,manufacture,Sales(Produced according to the specific range of varieties approved by the drug production license).Production,Sales of chemical intermediates,Plant extracts,Manage the chemical intermediates developed and produced by the company,Import and export trade business of plant extracts,Sales of chemical intermediates and plant extracts not produced by the company(The above business items do not include laws,Pre-approval and licensing items determined by regulations and the State Council).technology development,technology transfer,technical consulting.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)